Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently…
| Price | $1.17 |
|---|---|
| Market cap | $16.13M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 0.76-2.03 |
| Beta | 1.48 |
Explore COCP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.